Existing statistical measures and techniques in detecting and evaluating progressive supranuclear palsy, its phenotypes by using MRI modalities: A Review

被引：0

作者：

Sait N.A. ^{[1
]}

Kathirvelan J. ^{[1
]}

机构：

[1] SENSE, Vellore Institute of Technology, Vellore

来源：

Materials Today: Proceedings | 2023年 / 80卷

关键词：

Atrophy; Brain MRI; MRPI; Progressive supranuclear palsy; PSP criterions;

D O I：

10.1016/j.matpr.2021.06.044

中图分类号：

学科分类号：

摘要：

Progressive supranuclear palsy (PSP), is an atypical parkinsonian condition characterised by neurodegenerative disorders. Due to a high degree of overlap in characterised symptoms, clinically distinguishing PSP and atypical Parkinsonism traits at the onset is difficult. The review illustrates existing statistical measures and techniques that aid in the detection of certain brain atrophies that constitute to PSP and other atypical parkinsonian conditions using MRI image acquisition protocols. Finally, the review proposes machine learning methods with new models for programmed automated diagnosis as well as progressive methodology for identifying sensitive medical image biomarkers, in distinguishing PSP patients from other atypical parkinsonian ailments. © 2021

引用

页码：2000 / 2005

页数：5

共 53 条

[1]

Litvan I., Agid Y., Calne D., Et al., Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop, Neurology, 47, 1, pp. 1-9, (1996)

[2]

Williams D., Lees A., Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges, Lancet Neurol., 8, 3, pp. 270-279, (2009)

[3]

Steele J., Progressive supranuclear palsy, Arch Neurol., 10, 4, (1964)

[4]

Lamb R., Rohrer J., Lees A., Morris H., Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options, Curr. Treat. Options Neurol., 18, 9, (2016)

[5]

Hoglinger G., Melhem N., Dickson D., Et al., Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy, Nat. Genet., 43, 7, pp. 699-705, (2011)

[6]

Osaki Y., Ben-Shlomo Y., Lees A., Et al., Accuracy of clinical diagnosis of progressive supranuclear palsy, Mov. Disord., 19, 2, pp. 181-189, (2004)

[7]

Respondek G., Roeber S., Kretzschmar H., Et al., Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy, Mov. Disord., 28, 4, pp. 504-509, (2013)

[8]

Hoglinger, Et al., Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria, Mov. Disord., 32, 6, pp. 853-864, (2017)

[9]

Ling H., Clinical approach to progressive supranuclear palsy, J. Movement Dis., 9, 1, pp. 3-13, (2016)

[10]

Aerts M., Meijer F., Verbeek M., Esselink R., Bloem B., Diagnostic challenges in parkinsonism, Expert Rev. Neurother., 11, 8, pp. 1099-1101, (2011)

← 1 2 3 4 5 6 →